TickerFacts.

Compare

Repligen Corp vs BioCryst Pharmaceuticals Inc vs ADMA Biologics, Inc. vs Tarsus Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearRepligen Corp
RGEN		BioCryst Pharmaceuticals Inc
BCRX		ADMA Biologics, Inc.
ADMA		Tarsus Pharmaceuticals, Inc.
TARS
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$738.26M$874.84M$510.17M$451.36M
Revenue growth (YoY)+16.4%+94.1%+19.6%+146.7%
Gross margin52.3% (computed)n/a57.4%n/a
Operating margin7.5%39.0%37.5%-15.7%
Net margin6.6%30.2%28.8%-14.7%
Net income$48.89M$263.86M$146.93M-$66.42M
EPS (Diluted)$0.86$1.21$0.60-$1.59
Operating cash flow$117.42M$347.37M$50.40M-$12.45M
Free cash flow$93.90M$344.90M$27.82M-$22.31M
Cash & equivalents$566.02M$89.74M$87.63M$183.64M
Total assets$2.95B$514.16M$624.24M$562.16M
Total liabilities$843.57M$633.31M$146.92M$218.73M
Shareholders' equity$2.11B-$119.15M$477.32M$343.43M
Return on year-end equity2.3%n/a30.8%-19.3%
Shares outstanding56.33M213.06M237.87M42.55M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearRepligen CorpBioCryst Pharmaceuticals IncADMA Biologics, Inc.Tarsus Pharmaceuticals, Inc.
Latest$738.26M
Ended 2025-12-31		$874.84M
Ended 2025-12-31		$510.17M
Ended 2025-12-31		$451.36M
Ended 2025-12-31
1 year earlier$634.44M
Ended 2024-12-31		$450.71M
Ended 2024-12-31		$426.45M
Ended 2024-12-31		$182.95M
Ended 2024-12-31
2 years earlier$632.36M
Ended 2023-12-31		$331.41M
Ended 2023-12-31		$258.21M
Ended 2023-12-31		$17.45M
Ended 2023-12-31
3 years earlier$801.54M
Ended 2022-12-31		$270.83M
Ended 2022-12-31		$154.08M
Ended 2022-12-31		$25.82M
Ended 2022-12-31
4 years earlier$670.53M
Ended 2021-12-31		$157.17M
Ended 2021-12-31		$80.94M
Ended 2021-12-31		$57.03M
Ended 2021-12-31